CytoSorbents (STU:HQE) Tariff Resilience Score: 5/10 (As of Sep. 11, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:HQE CytoSorbents Corp STU:HQE
45 GF Score
Price €5.92
GF Value €16.19
! 5 Warning Signs
View Full Analysis

What is CytoSorbents Tariff Resilience Score?

CytoSorbents STU:HQE 45 Tariff Resilience Score is 5 as of Sep. 11, 2026. GuruFocus rates STU:HQE with a GF Score™ of 45/100 and a GF Value™ of €16.19. The stock has 5 warning signs investors should review. Among 825 Medical Devices & Instruments companies, CytoSorbents ranks better than 79.03% on this metric.

CytoSorbents has the Tariff Resilience Score of 5, which implies that the company might have Average Resilient.

CytoSorbents has CytoSorbents relies on international markets for both supply and sales. While it has faced some tariff impacts, its niche medical products may benefit from exemptions. However, limited pricing power poses a risk.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes CytoSorbents might have Average Resilient.

CytoSorbents  (STU:HQE) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

CytoSorbents Tariff Resilience Score Related Terms

STU:HQE vs LFWD, GTHP, PMI: Tariff Resilience Score Comparison

For the Medical Devices subindustry, CytoSorbents's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CytoSorbents Tariff Resilience Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, CytoSorbents's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where CytoSorbents's Tariff Resilience Score falls into.


STU:HQE
45GF Score
CytoSorbents Corp STU:HQE
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 5 mean?
CytoSorbents (STU:HQE) has a Tariff Resilience Score of 5 as of Sep. 11, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, CytoSorbents ranks #173 out of 825 companies in the Medical Devices & Instruments industry, placing it in the top 21%.
Is CytoSorbents' Tariff Resilience Score too high?
CytoSorbents' current Tariff Resilience Score is 5. Based on the distribution chart, CytoSorbents ranks #173 out of 825 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, CytoSorbents has a GF Score™ of 45/100, reflecting its overall financial health beyond just this single metric.
How does CytoSorbents' Tariff Resilience Score compare to LFWD and GTHP?
According to the Medical Devices & Instruments industry distribution chart, CytoSorbents ranks #173 out of 825 companies for Tariff Resilience Score. This places CytoSorbents in the top 21% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Medical Devices & Instruments company?
A good Tariff Resilience Score depends on the Medical Devices & Instruments industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. CytoSorbents's current Tariff Resilience Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CytoSorbents stock overvalued right now?
CytoSorbents (STU:HQE) has a current Tariff Resilience Score of 5. The stock's GF Value™ is €16.19, compared to a current price of €5.92 — trading 63.4% below its estimated fair value. The current Tariff Resilience Score is 5. CytoSorbents' overall GF Score™ is 45/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For CytoSorbents (STU:HQE), the current Tariff Resilience Score is 5 as of Sep. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CytoSorbents (STU:HQE) Overvalued in 2026?

Based on GuruFocus' analysis, CytoSorbents stock appears to be undervalued. The current stock price of €5.92 is trading 63.4% below its estimated GF Value™ of €16.19.

Key valuation signals for STU:HQE:

  • Tariff Resilience Score: 5
  • GF Value™: €16.19 vs. price of €5.92 (63.4% below fair value)
  • GF Score™: 45/100 with 5 warning signs

No single metric tells the full story. See the STU:HQE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CytoSorbents Business Description

Other Exchanges CTSO:USA
Address 305 College Road East, Princeton, NJ, USA, 08540
CytoSorbents Corp is a leader in blood purification for the treatment of life-threatening conditions in the intensive care unit and cardiac surgery. CytoSorbent's proprietary blood purification technologies are based on biocompatible, high-porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbent's technologies are used in several broad applications. Specifically, two important applications are: the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and the removal of inflammatory agents and toxins in common critical illnesses that can cause massive inflammation, organ failure, and patient death. Geographically, in the USA, Germany, and Others.
45GF Score

Get the complete analysis for STU:HQE

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.92
Price
€16.19
GF Value